154 related articles for article (PubMed ID: 22712026)
1. Cetuximab in refractory skin cancer treatment.
Kalapurakal SJ; Malone J; Robbins KT; Buescher L; Godwin J; Rao K
J Cancer; 2012; 3():257-61. PubMed ID: 22712026
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
Blick SK; Scott LJ
Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592
[TBL] [Abstract][Full Text] [Related]
4. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.
Wollina U; Tchernev G; Lotti T
Open Access Maced J Med Sci; 2018 Jan; 6(1):152-155. PubMed ID: 29484016
[TBL] [Abstract][Full Text] [Related]
7. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
8. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
Frampton JE
Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on cetuximab in squamous cell carcinoma of the head and neck.
Frampton JE
BioDrugs; 2011 Apr; 25(2):129-33. PubMed ID: 21443275
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
12. Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.
Della Vittoria Scarpati G; Perri F; Pisconti S; Costa G; Ricciardiello F; Del Prete S; Napolitano A; Carraturo M; Mazzone S; Addeo R
Mol Clin Oncol; 2016 Apr; 4(4):467-471. PubMed ID: 27073643
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
15. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Bauman JE; Eaton KD; Martins RG
Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
[TBL] [Abstract][Full Text] [Related]
20. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study.
Hughes S; Liong J; Miah A; Ahmad S; Leslie M; Harper P; Prendiville J; Shamash J; Subramaniam R; Gaya A; Spicer J; Landau D
J Thorac Oncol; 2008 Jun; 3(6):648-51. PubMed ID: 18520806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
